Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of 10x Genomics Inc (NASDAQ: TXG) closed at $13.91 in the last session, down -0.64% from day before closing price of $14.0. In other words, the price has decreased by -$0.64 from its previous closing price. On the day, 2.61 million shares were traded. TXG stock price reached its highest trading level at $14.3196 during the session, while it also had its lowest trading level at $13.59.
Ratios:
We take a closer look at TXG’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.07 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 38.29. For the most recent quarter (mrq), Quick Ratio is recorded 4.68 and its Current Ratio is at 5.37. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on February 13, 2025, Downgraded its rating to Market Perform and sets its target price to $12 from $25 previously.
On September 03, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $35.
Jefferies Upgraded its Hold to Buy on July 22, 2024, while the target price for the stock was maintained at $24.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 22 ’25 when Saxonov Serge sold 9,343 shares for $8.30 per share. The transaction valued at 77,540 led to the insider holds 1,083,625 shares of the business.
Hindson Benjamin J. sold 7,485 shares of TXG for $62,120 on May 22 ’25. The insider now owns 448,374 shares after completing the transaction at $8.30 per share. On May 22 ’25, another insider, Taich Adam, who serves as the Chief Financial Officer of the company, sold 4,044 shares for $8.30 each. As a result, the insider received 33,562 and left with 331,588 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TXG now has a Market Capitalization of 1712793984 and an Enterprise Value of 1365959424. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.78 while its Price-to-Book (P/B) ratio in mrq is 2.42. Its current Enterprise Value per Revenue stands at 2.187 whereas that against EBITDA is -9.3.
Stock Price History:
The Beta on a monthly basis for TXG is 2.04, which has changed by -0.29319108 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, TXG has reached a high of $24.76, while it has fallen to a 52-week low of $6.78. The 50-Day Moving Average of the stock is 24.23%, while the 200-Day Moving Average is calculated to be 13.11%.
Shares Statistics:
According to the various share statistics, TXG traded on average about 3.84M shares per day over the past 3-months and 3133680 shares per day over the past 10 days. A total of 109.08M shares are outstanding, with a floating share count of 105.77M. Insiders hold about 15.28% of the company’s shares, while institutions hold 90.32% stake in the company. Shares short for TXG as of 1752537600 were 14263062 with a Short Ratio of 3.72, compared to 1749772800 on 13434164. Therefore, it implies a Short% of Shares Outstanding of 14263062 and a Short% of Float of 19.209999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of 10x Genomics Inc (TXG) is currently in the spotlight, with 2.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.01, with high estimates of $0.04 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.02 and -$0.18 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is -$0.03, with 2.0 analysts recommending between $0.06 and -$0.11.
Revenue Estimates
According to 13 analysts, the current quarter’s revenue is expected to be $139.51M. It ranges from a high estimate of $140.62M to a low estimate of $137.79M. As of the current estimate, 10x Genomics Inc’s year-ago sales were $153.1MFor the next quarter, 13 analysts are estimating revenue of $144.53M. There is a high estimate of $157.01M for the next quarter, whereas the lowest estimate is $139M.
A total of 15 analysts have provided revenue estimates for TXG’s current fiscal year. The highest revenue estimate was $631.43M, while the lowest revenue estimate was $571.59M, resulting in an average revenue estimate of $590.68M. In the same quarter a year ago, actual revenue was $610.78MBased on 15 analysts’ estimates, the company’s revenue will be $621.92M in the next fiscal year. The high estimate is $690.27M and the low estimate is $581.37M.
